NCT04546633: Efficacy, Safety and Tolerability of KAF156 in Combination With Lumefantrine Solid Dispersion Formulation (LUM-SDF) in Pediatric Population With Uncomplicated Plasmodium Falciparum Malaria |
|
|
| Completed | 2 | 295 | RoW | KAF156, LUM-SDF, Lumefantrine Solid Dispersion Formulation, Coartem | Novartis Pharmaceuticals, European and Developing Countries Clinical Trials Partnership (EDCTP) | Uncomplicated Plasmodium Falciparum Malaria | 08/24 | 08/24 | | |
2021-003583-27: Efficacy, safety and tolerability of KAF156 in combination with LUM-SDF in pediatric population with uncomplicated Plasmodium falciparum malaria Efficacité, sécurité et tolérabilité du KAF156 en association avec la LUM-SDF dans une population pédiatrique atteinte de paludisme non compliqué à Plasmodium falciparum |
|
|
| Not yet recruiting | 2 | 220 | RoW | KAF156, Lumefantrine-SDF, LUM566, , Film-coated tablet, Granules for oral suspension in sachet, RIAMET® Dispersible | Novartis Pharma AG, Novartis Pharma AG, Medicines for Malaria Venture, European and Developing Countries Clinical Trials Partnership | Plasmodium Falciparum Malaria, Uncomplicated malaria, Diseases [C] - Parasitic Diseases [C03] | | | | |
